Baxter gets rights to Chatham’s hemophilia B gene therapeutic AskBio009
Chatham Therapeutics LLC (the hemophilia-focused affiliate of large-molecule delivery company Asklepios BioPharmaceutical Inc. (AskBio)) has licensed Baxter BioScience (the recombinant and plasma-based proteins division of Baxter International Inc.’s Baxter Healthcare Corp.) exclusive worldwide rights to its Phase I gene therapeutic AskBio009 for hemophilia B, a single-gene disorder caused by deficient gene coding on the X chromosome of the blood clotting Factor IX.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
- Nanotechnology, Chips, etc.
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com